CB Therapeutics opens biosynthesis platform as psychedelic supply pressures build

By AI, Created 4:19 PM UTC, May 18, 2026, /AGP/ – CB Therapeutics is pitching its yeast-based manufacturing platform to developers after the April 18 U.S. executive order on psychedelic medicines added federal momentum to the field. The company says supply, not demand, is becoming the main bottleneck as more compounds move toward clinical and commercial use.

Why it matters: - The April 18, 2026 U.S. Executive Order on Psychedelic Medicines added federal support for the field by committing $50 million to ibogaine research, creating priority review vouchers for qualifying psychedelic compounds and opening a Right-to-Try pathway for investigational psychedelics. - The policy shift raises the odds that more psychedelic medicines move from research into development, which makes manufacturing capacity and repeatable supply a practical hurdle. - CB Therapeutics is positioning its synthetic biology platform as part of the answer for compounds that are hard to extract from plants or make cheaply through chemical synthesis.

What happened: - CB Therapeutics, a Carlsbad, California-based synthetic biology company, said it is opening its biosynthesis platform to new research and commercial partners. - The company said it is engaging clinical-stage developers, ingredient and commercial partners, and synthetic biology platforms across its active programs. - The active programs include TryptageniX for rare and complex alkaloids, TryptageniX AI for synbio datasets for AI agents, Korvane for pain therapeutics and Aevora for therapeutic peptides. - The company operates a Carlsbad-based pilot biomanufacturing facility.

The details: - The monoterpene indole alkaloid family includes compounds such as vincristine, vinblastine and quinine, along with molecules under investigation for mental health and addiction. - Strictosidine is the common biosynthetic precursor for the monoterpene indole alkaloid family. - CB Therapeutics says it has engineered yeast strains that produce strictosidine and route it into downstream monoterpene indole alkaloid programs through subsidiary TryptageniX. - The company says its intellectual property portfolio is among the larger private synthetic biology portfolios for psychedelic and natural-product compounds. - Sher Ali Butt, CEO and co-founder, said the executive order moves these molecules from the margins of medicine to a national priority and that clinical-stage developers will need partners with scientific, regulatory and manufacturing depth. - Jacob Vogan, chief scientific officer and co-founder, said many of the relevant compounds have never been produced outside the plant or fungus and that biosynthesis with affordable feedstocks, paired with AI, is how the chemistry becomes accessible.

Between the lines: - The press release frames supply as the next constraint because the easier part may be getting regulatory attention, not producing enough material consistently and at scale. - The emphasis on yeast-based biosynthesis signals a bet that precision fermentation can outperform plant extraction on reliability and expand access to rare molecules. - The reference to AI suggests CB Therapeutics wants to be more than a contract manufacturer and instead position its data and production stack as infrastructure for drug developers. - The release also links psychedelic medicines to a broader natural-products platform, which could broaden the company’s commercial opportunities beyond one therapeutic category.

What’s next: - CB Therapeutics is seeking partnerships with clinical-stage developers and commercial partners as psychedelic programs advance. - The company is also leaning on its biosynthesis platform and pilot facility to support future scale-up needs. - The release points to continued regulatory and commercial activity in the U.S. and abroad, including moves in the Czech Republic, Germany and Australia.

The bottom line: - CB Therapeutics is betting that the next winners in psychedelic medicine will be the companies that can solve supply, not just science.